Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00075491
Other study ID # NCI-2012-02566
Secondary ID ID02-701R21CA097
Status Terminated
Phase Phase 2
First received January 9, 2004
Last updated January 23, 2013
Start date December 2003

Study information

Verified date January 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This randomized phase II trial is studying how well neoadjuvant and adjuvant fenretinide works compared to adjuvant fenretinide alone in treating patients who are undergoing surgical resection for recurrent glioblastoma multiforme. Chemotherapy drugs, such as fenretinide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed. Giving chemotherapy after surgery may kill any remaining tumor cells. It is not yet known whether neoadjuvant and adjuvant fenretinide is more effective than adjuvant fenretinide alone


Description:

PRIMARY OBJECTIVES:

I. Compare the efficacy of neoadjuvant and adjuvant fenretinide vs adjuvant fenretinide alone, in terms of 6-month progression-free survival, in patients with recurrent glioblastoma multiforme undergoing surgical resection II. Correlate the serum and glioma tissue pharmacology of this drug with clinical response in patients treated with these regimens.

III. Determine whether this drug induces apoptosis in glioma tissue in patients treated with these regimens.

IV. Correlate the apoptotic index with tissue and serum concentration and clinical response in patients treated with these regimens.

V. Compare radiological response, overall survival, and unexpected toxicity in patients treated with these regimens.

OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo surgical resection.

Arm II: Patients undergo surgical resection.

Beginning two weeks after surgery, all patients receive adjuvant oral fenretinide twice daily on weeks 1 and 4. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 21-46 patients (10-23 per treatment arm) will be accrued for this study within 7-46 months.


Recruitment information / eligibility

Status Terminated
Enrollment 42
Est. completion date
Est. primary completion date March 2005
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed glioblastoma multiforme after initial tumor resection

- Radiologically evident recurrent tumor after prior radiotherapy OR after treatment for no more than 2 prior relapses

- Enhancing or nonenhancing recurrent disease by MRI

- No progressive symptoms requiring urgent surgery

- Performance status - Karnofsky 70-100%

- More than 8 weeks

- Absolute granulocyte count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- PT/PTT no greater than upper limit of normal

- SGPT no greater than 2.5 times normal

- Alkaline phosphatase no greater than 2.5 times normal

- Bilirubin less than 1.5 mg/dL

- BUN no greater than 1.5 times normal

- Creatinine no greater than 1.5 times normal

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective barrier contraception during and for 2 months after study participation

- Amylase and lipase normal

- No active infection

- No other disease that would obscure toxicity or dangerously alter drug metabolism

- No other concurrent serious medical illness

- Not at risk from any study treatment delays

- Able to swallow fenretinide capsules

- Recovered from all prior chemotherapy

- Approximately 2 weeks since prior vincristine

- Approximately 6 weeks since prior nitrosoureas

- Approximately 3 weeks since prior procarbazine

- See Disease Characteristics

- At least 2 weeks since prior radiotherapy

- See Disease Characteristics

- At least 1 week since prior vitamin A

- At least 1 week since prior isotretinoin (Accutane®)

- No concurrent vitamin A during and for 2 weeks after study participation

- No concurrent antioxidants (e.g., ascorbic acid or vitamin E)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Intervention

Drug:
fenretinide
Given orally
Procedure:
therapeutic conventional surgery
Undergo surgery
Other:
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival (PFS) Up to 6 months No
Primary Plasma and tissue concentrations of fenretinide and its metabolite, 4-MPR using high-performance liquid chromatography (HPLC) assay At baseline, and at 1, 7, 14, and 21 days No
Primary Tumor apoptotic index after fenretinide treatment by immunohistochemistry At the time of surgery No
Primary Correlation between tumor apoptotic index with serum and tissue fenretinide levels At the time of surgery No
Primary Correlation of time to progression with drug levels and apoptotic index Up to 2 years No
Secondary Fenretinide effects on retinol, RBP, retinoid receptor levels and IGF-1 Up to 21 days (course 1 and 4) No
Secondary Fenretinide activity using magnetic resonance spectroscopy (MRS) At the time of surgery No
Secondary Radiological response Up to 2 years No
Secondary Overall survival Up to 2 years No
Secondary Unexpected toxicity associated with fenretinide as assessed by CTC version 3.0 Up to 2 years Yes
See also
  Status Clinical Trial Phase
Terminated NCT02530502 - Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Phase 1
Withdrawn NCT02194452 - Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors N/A
Completed NCT00238303 - Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Phase 2
Completed NCT02227901 - Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1
Completed NCT00049387 - Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Phase 1
Completed NCT02015819 - Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Phase 1
Active, not recruiting NCT02179086 - Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Phase 2
Recruiting NCT04573140 - A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) Phase 1
Active, not recruiting NCT00823797 - Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Phase 2
Completed NCT00045565 - Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Completed NCT01977677 - Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Phase 1/Phase 2
Completed NCT01648348 - Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00004262 - Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme Phase 1
Terminated NCT01575275 - Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme Phase 2
Terminated NCT01996527 - 3T MRI Biomarkers of Glioma Treatment Response Early Phase 1
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT01103375 - Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma Phase 1
Completed NCT01119599 - RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Completed NCT00459381 - Pazopanib in Treating Patients With Recurrent Glioblastoma Phase 2
Completed NCT00316849 - Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1